DURECT Corporation (DRRX)
USD 0.6
(3.1%)
USD 0.6
(3.1%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 20.74 Million USD | -10.82% |
| 2022 | 23.26 Million USD | -4.29% |
| 2021 | 24.3 Million USD | -5.86% |
| 2020 | 25.81 Million USD | -3.75% |
| 2019 | 26.82 Million USD | 30.63% |
| 2018 | 20.53 Million USD | 3.1% |
| 2017 | 19.91 Million USD | 1957.33% |
| 2016 | 968 Thousand USD | -95.08% |
| 2015 | 19.68 Million USD | -0.71% |
| 2014 | 19.82 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 508 Thousand USD | -22.56% |
| 2008 | 656 Thousand USD | -97.28% |
| 2007 | 24.08 Million USD | -36.94% |
| 2006 | 38.18 Million USD | -40.86% |
| 2005 | 64.56 Million USD | 5.13% |
| 2004 | 61.41 Million USD | -0.67% |
| 2003 | 61.83 Million USD | 2997.95% |
| 2002 | 1.99 Million USD | -25.49% |
| 2001 | 2.67 Million USD | 77.18% |
| 2000 | 1.51 Million USD | 369.57% |
| 1999 | 322 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 16.06 Million USD | -12.58% |
| 2024 Q1 | 18.37 Million USD | -11.42% |
| 2023 Q2 | 22.84 Million USD | -0.48% |
| 2023 Q1 | 22.95 Million USD | -1.31% |
| 2023 Q4 | 20.74 Million USD | -10.4% |
| 2023 FY | 20.74 Million USD | -10.82% |
| 2023 Q3 | 23.15 Million USD | 1.34% |
| 2022 FY | 23.26 Million USD | -4.29% |
| 2022 Q1 | 24.06 Million USD | -0.97% |
| 2022 Q3 | 23.54 Million USD | -1.13% |
| 2022 Q2 | 23.81 Million USD | -1.06% |
| 2022 Q4 | 23.26 Million USD | -1.2% |
| 2021 Q1 | 25.64 Million USD | -0.66% |
| 2021 FY | 24.3 Million USD | -5.86% |
| 2021 Q4 | 24.3 Million USD | -0.88% |
| 2021 Q2 | 24.72 Million USD | -3.6% |
| 2021 Q3 | 24.52 Million USD | -0.82% |
| 2020 Q3 | 26.22 Million USD | -0.81% |
| 2020 Q1 | 26.64 Million USD | -0.68% |
| 2020 FY | 25.81 Million USD | -3.75% |
| 2020 Q4 | 25.81 Million USD | -1.56% |
| 2020 Q2 | 26.43 Million USD | -0.75% |
| 2019 Q4 | 26.82 Million USD | -3.57% |
| 2019 Q2 | 27.96 Million USD | -0.51% |
| 2019 Q1 | 28.1 Million USD | 36.9% |
| 2019 Q3 | 27.81 Million USD | -0.54% |
| 2019 FY | 26.82 Million USD | 30.63% |
| 2018 Q3 | 19.89 Million USD | 0.15% |
| 2018 FY | 20.53 Million USD | 3.1% |
| 2018 Q1 | 19.83 Million USD | -0.41% |
| 2018 Q2 | 19.86 Million USD | 0.14% |
| 2018 Q4 | 20.53 Million USD | 3.23% |
| 2017 Q2 | 19.88 Million USD | 0.08% |
| 2017 Q1 | 19.86 Million USD | 1952.58% |
| 2017 FY | 19.91 Million USD | 1957.33% |
| 2017 Q3 | 19.89 Million USD | 0.08% |
| 2017 Q4 | 19.91 Million USD | 0.08% |
| 2016 Q3 | 19.83 Million USD | 0.44% |
| 2016 Q1 | 19.71 Million USD | 0.17% |
| 2016 Q2 | 19.75 Million USD | 0.17% |
| 2016 Q4 | 968 Thousand USD | -95.12% |
| 2016 FY | 968 Thousand USD | -95.08% |
| 2015 Q3 | 19.65 Million USD | -1.07% |
| 2015 Q4 | 19.68 Million USD | 0.17% |
| 2015 FY | 19.68 Million USD | -0.71% |
| 2015 Q1 | 19.84 Million USD | 0.1% |
| 2015 Q2 | 19.86 Million USD | 0.1% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | 19.78 Million USD | 0.0% |
| 2014 FY | 19.82 Million USD | 0.0% |
| 2014 Q3 | 19.8 Million USD | 0.1% |
| 2014 Q4 | 19.82 Million USD | 0.1% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | -100.0% |
| 2009 Q4 | 508 Thousand USD | 0.0% |
| 2009 FY | 508 Thousand USD | -22.56% |
| 2009 Q1 | 667 Thousand USD | 1.68% |
| 2009 Q2 | 614 Thousand USD | -7.95% |
| 2009 Q3 | - USD | -100.0% |
| 2008 Q1 | 23.59 Million USD | -2.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | -100.0% |
| 2008 FY | 656 Thousand USD | -97.28% |
| 2008 Q4 | 656 Thousand USD | 0.0% |
| 2007 Q2 | 38.1 Million USD | -0.18% |
| 2007 FY | 24.08 Million USD | -36.94% |
| 2007 Q4 | 24.08 Million USD | -29.11% |
| 2007 Q1 | 38.17 Million USD | -0.02% |
| 2007 Q3 | 33.97 Million USD | -10.86% |
| 2006 Q4 | 38.18 Million USD | -0.54% |
| 2006 Q3 | 38.39 Million USD | -0.02% |
| 2006 Q2 | 38.4 Million USD | -34.2% |
| 2006 Q1 | 58.36 Million USD | -9.61% |
| 2006 FY | 38.18 Million USD | -40.86% |
| 2005 Q2 | 69.01 Million USD | 12.5% |
| 2005 Q3 | 58.53 Million USD | -15.18% |
| 2005 Q4 | 64.56 Million USD | 10.31% |
| 2005 FY | 64.56 Million USD | 5.13% |
| 2005 Q1 | 61.34 Million USD | -0.12% |
| 2004 Q3 | 61.67 Million USD | -0.04% |
| 2004 Q4 | 61.41 Million USD | -0.41% |
| 2004 FY | 61.41 Million USD | -0.67% |
| 2004 Q1 | 61.76 Million USD | -0.11% |
| 2004 Q2 | 61.69 Million USD | -0.11% |
| 2003 Q1 | 2.21 Million USD | 11.07% |
| 2003 FY | 61.83 Million USD | 2997.95% |
| 2003 Q2 | 52.14 Million USD | 2252.14% |
| 2003 Q3 | 3.14 Million USD | -93.96% |
| 2003 Q4 | 61.83 Million USD | 1863.64% |
| 2002 Q3 | 2.11 Million USD | -11.67% |
| 2002 Q4 | 1.99 Million USD | -5.8% |
| 2002 Q1 | 2.53 Million USD | -5.34% |
| 2002 Q2 | 2.39 Million USD | -5.4% |
| 2002 FY | 1.99 Million USD | -25.49% |
| 2001 FY | 2.67 Million USD | 77.18% |
| 2001 Q4 | 2.67 Million USD | -9.4% |
| 2001 Q3 | 2.95 Million USD | -3.52% |
| 2001 Q2 | 3.06 Million USD | 113.44% |
| 2001 Q1 | 1.43 Million USD | -5.03% |
| 2000 FY | 1.51 Million USD | 369.57% |
| 2000 Q3 | 1.24 Million USD | 26.8% |
| 2000 Q4 | 1.51 Million USD | 21.06% |
| 2000 Q2 | 985 Thousand USD | 0.0% |
| 1999 FY | 322 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 96.165% |
| Theratechnologies Inc. | 58.96 Million USD | 64.818% |
| Safety Shot Inc | 1.54 Million USD | -1239.338% |
| Cosmos Health Inc. | 12.42 Million USD | -66.984% |
| Cronos Group Inc. | 2.53 Million USD | -716.792% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 97.101% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 42.885% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 82.618% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -278.407% |
| ProPhase Labs, Inc. | 21.38 Million USD | 2.965% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -3312.171% |
| Dynavax Technologies Corporation | 256.91 Million USD | 91.925% |
| Radius Health, Inc. | 365.31 Million USD | 94.321% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -683.62% |
| Alvotech | 1.07 Billion USD | 98.071% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -3054.302% |
| Alpha Teknova, Inc. | 30.45 Million USD | 31.887% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -22.482% |
| SCYNEXIS, Inc. | 15.08 Million USD | -37.573% |
| Harrow Health, Inc. | 190.5 Million USD | 89.11% |
| Biofrontera Inc. | 5.39 Million USD | -284.256% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 50.042% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 93.421% |
| OptiNose, Inc. | 131.74 Million USD | 84.253% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -1668.618% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 79.007% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -12.576% |
| SIGA Technologies, Inc. | 1.46 Million USD | -1317.068% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 84.086% |
| Shineco, Inc. | 29.65 Million USD | 30.046% |
| Phibro Animal Health Corporation | 525.45 Million USD | 96.052% |
| Procaps Group S.A. | 285.93 Million USD | 92.745% |
| TherapeuticsMD, Inc. | 8 Million USD | -159.163% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -34588.247% |
| Viatris Inc. | 18.12 Billion USD | 99.886% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -3054.302% |
| Rockwell Medical, Inc. | 13.43 Million USD | -54.372% |
| Incannex Healthcare Limited | 373 Thousand USD | -5461.93% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -37.127% |
| Tilray Brands, Inc. | 387.31 Million USD | 94.644% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 96.923% |
| PetIQ, Inc. | 468.3 Million USD | 95.57% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 95.157% |
| Journey Medical Corporation | 17.73 Million USD | -17.011% |
| Alimera Sciences, Inc. | 67.39 Million USD | 69.219% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -150.659% |
| Assertio Holdings, Inc. | 40.91 Million USD | 49.291% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -1807.338% |
| Embecta Corp. | 1.63 Billion USD | 98.734% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -1908.102% |
| Procaps Group, S.A. | 285.93 Million USD | 92.745% |
| PainReform Ltd. | 86 Thousand USD | -24023.256% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 41.369% |
| Hempacco Co., Inc. | 13.72 Million USD | -51.16% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 96.46% |
| Alvotech | 1.07 Billion USD | 98.071% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 96.637% |
| Kamada Ltd. | 8.74 Million USD | -137.125% |
| Indivior PLC | 281.6 Million USD | 92.633% |
| Currenc Group, Inc. | 31.94 Million USD | 35.054% |
| Evoke Pharma, Inc. | 5 Million USD | -314.92% |
| Flora Growth Corp. | 3.67 Million USD | -464.978% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -1908.102% |
| Evolus, Inc. | 126.54 Million USD | 83.606% |
| HUTCHMED (China) Limited | 86.13 Million USD | 75.913% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 96.673% |
| Akanda Corp. | 3.99 Million USD | -418.807% |